TherapeuticsMD Inc (NYSEMKT:TXMD) Investor Investigation Concerning Potential Securities Laws Violations Announced

If you purchased shares of TherapeuticsMD Inc (NYSEMKT:TXMD), you have certain options and you should contact the Shareholders Foundation, Inc.

To have your information reviewed for options and to recieve notifications about this investigation, please use this form. You may also send an email to mail@shareholdersfoundation.com, or call us at (858) 779-1554.
Company Name(s): 
TherapeuticsMD
Affected Securities: 
NYSEMKT: TXMD

April 17, 2017 (Shareholders Foundation) - An investigation on behalf of investors of TherapeuticsMD Inc (NYSEMKT:TXMD) shares over potential securities laws violations by TherapeuticsMD Inc and certain of its directors and officers in connection certain financial statements was announced.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of TherapeuticsMD Inc (NYSEMKT:TXMD) concerning whether a series of statements by TherapeuticsMD Inc regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

Boca Raton, FL based TherapeuticsMD, Inc. is a women's healthcare company engaged in creating and commercializing products for women. TherapeuticsMD Inc is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. TherapeuticsMD Inc reported that its annual Total Revenue declined from $20.14 million in 2015 to $19.36 million in 2016 and that its Net Loss increased from $85.08 million in 2015 to $89.88 million in 2016.

On April 10, 2017, TherapeuticsMD Inc announced receipt of a letter from the U.S. Food and Drug Administration (“FDA”stating that its ongoing review of the Company’s New Drug Application (NDA) for TX-004HR has discovered “deficiencies that preclude discussion of labeling and postmarketing requirements/commitments at this time.

Shares of TherapeuticsMD Inc (NYSEMKT:TXMD) declined on April 17, 2017 to $5.14 per share.